{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:49:38Z","timestamp":1791985778818,"version":"4.4.0"},"reference-count":57,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T00:00:00Z","timestamp":1187827200000},"content-version":"vor","delay-in-days":4313,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[1995,11]]},"abstract":"<jats:p>Seventy\u2010seven patients with a primary diagnosis of social phobia (DSM\u2010III\u2010R) were randomized to treatment with the reversible and selective monoamine oxidase type A inhibitor brofaromine (<jats:italic>n<\/jats:italic>= 37) or placebo (<jats:italic>n<\/jats:italic>= 40) for 12 weeks in a double\u2010blind trial. A fixed dose of 150 mg\/day or a matching placebo was given after a 2\u2010week dose titration phase. Patients with additional diagnoses of simple phobia, generalized anxiety disorder, dysthymia or major depressive disorder currently in remission were accepted. Patients with other Axis I mental disorders were excluded. In the brofaromine group, 78% of the patients scored much or very much improved on the Clinical Global Impression scale compared with 23% in the placebo group. The anxiety and avoidance scores on the Liebowitz Social Anxiety Scale (LSAS) were significantly reduced in favor of brofaromine. The clinical effects were not significantly correlated with the plasma concentration of brofaromine. After 12 weeks the brofaromine group scored significantly Jower than the placebo group on a core depression part of the Montgomery\u2010\u00c5sberg Depressid Rating Scale. After 12 weeks of treatment the brofaromine group had significantly higher total scores on the LSAS than an age\u2010 and gender\u2010matched group of healthy controls. The brofaromine group improved further during 9\u2010month follow\u2010up treatment period, whereas 60% of the placebo responders who continued long\u2010term treatment relapsed. The most common side effects in the brofaromine group were sleep disturbances, dry mouth and nausea.<\/jats:p>","DOI":"10.1111\/j.1600-0447.1995.tb09596.x","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T13:45:19Z","timestamp":1187876719000},"page":"351-358","source":"Crossref","is-referenced-by-count":87,"title":["Social phobia: the clinical efficacy and tolerability of the monoamine oxidase \u2010A and serotonin uptake inhibitor brofaromine. A double\u2010blind placebo\u2010controlled study"],"prefix":"10.1111","volume":"92","author":[{"given":"T.","family":"Fahl\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. L.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Humble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Pauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,8,23]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1985.01790300097013"},{"key":"e_1_2_1_3_2","first-page":"10","article-title":"Treatment of social phobia with drugs other than benzodiazepines.","volume":"52","author":"Liebowitz MR","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_4_2","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association.","year":"1980"},{"key":"e_1_2_1_5_2","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association.","year":"1987"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.142.2.174"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.149.4.464"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0887-6185(91)90031-N"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0887-6185(90)90023-3"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.147.5.637"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/archpsyc.1992.01820040034004","article-title":"Social phobia. Comorbidity and morbidity in an epidemiologic sample","volume":"49","author":"Schneier FR","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(91)90055-W"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.147.8.1025"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(92)90020-7"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.8.1216"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950050015002"},{"key":"e_1_2_1_17_2","first-page":"59","article-title":"Comorbidity of panic disorder and social phobia","volume":"7","author":"Andersch SEO","year":"1993","journal-title":"Eur J Psychiatry"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.146.2.235"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1988.62.1.323"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.116.533.387"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00422146"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198604000-00006"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198808000-00008"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.49.4.290"},{"issue":"6","key":"e_1_2_1_25_2","first-page":"33","article-title":"Medication therapy for social phobia.","volume":"55","author":"Marshall RD","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0924-977X(92)90032-4"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.161.3.353"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244762"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199312000-00008"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1159\/000407502"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(83)90443-0"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90016-2"},{"issue":"2","key":"e_1_2_1_33_2","first-page":"S19","article-title":"Brofaromine: a monoamine oxidase\u2010A and serotonin uptake inhibitor.","volume":"16","author":"Waldmeier PC","year":"1993","journal-title":"Clin Neuropharmacol"},{"issue":"28","key":"e_1_2_1_34_2","first-page":"5","article-title":"Preclinical profiles of the novel reversible MAO\u2010A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors","author":"Da Prada M","year":"1989","journal-title":"J Neural Transm"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.26"},{"key":"e_1_2_1_36_2","first-page":"33","article-title":"Therapeutic and side\u2010effect profile of a selective and reversible MAO\u2010A inhibitor, brofaromine: results of dose\u2010finding trials in depressed patients","volume":"28","author":"Schiwy W","year":"1989","journal-title":"J Neural Transm"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(94)90068-X"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199201001-00225"},{"key":"e_1_2_1_39_2","first-page":"211","article-title":"Brofaromine (CGP 11305 A) in the treatment of panic disorders","volume":"22","author":"\u00d6zdaglar A","year":"1989","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"e_1_2_1_40_2","first-page":"0","article-title":"Brofaromine and clomipramine in panic disorder.","volume":"15","author":"Saxena B","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199202001-00175"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199312000-00007"},{"key":"e_1_2_1_43_2","volume-title":"Instruction manual for the Structured Clinical Interview for DSM\u2010III\u2010R. SCID 5\/1\/89 revision edition","author":"Spitzer RL","year":"1989"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8260.1967.tb00530.x"},{"issue":"2","key":"e_1_2_1_45_2","first-page":"200","article-title":"Overview of clinical investigations with brofaromine.","volume":"13","author":"Snaith J.","year":"1990","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_1_46_2","first-page":"141","volume-title":"Anxiety","author":"Liebowitz MR.","year":"1987"},{"key":"e_1_2_1_47_2","volume-title":"ECDEU Assessment manual for psychopharmacology, revised","author":"Guy W.","year":"1976"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_1_50_2","volume-title":"Manual for the State\u2010Trait Anxiety Inventory (Form Y)","author":"Spielberger CD","year":"1983"},{"key":"e_1_2_1_51_2","first-page":"13","article-title":"SCL\u201090: An outpatient psychiatric rating scale: preliminary report","volume":"9","author":"Derogatis LR","year":"1973","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(79)90021-1"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-0525-3_7"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.2307\/1130685"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1037\/0003-066X.44.4.668"},{"issue":"6","key":"e_1_2_1_56_2","first-page":"10","article-title":"The etiology of social phobia.","volume":"55","author":"Rosenbaum JF","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/0731-7085(93)80205-F"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199503010-00001"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0447.1995.tb09596.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0447.1995.tb09596.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T19:14:03Z","timestamp":1698261243000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0447.1995.tb09596.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,11]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1995,11]]}},"alternative-id":["10.1111\/j.1600-0447.1995.tb09596.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0447.1995.tb09596.x","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,11]]}}}